BELITE BIO INC - ADR (BLTE) Fundamental Analysis & Valuation

NASDAQ:BLTE • US07782B1044

Current stock price

152.07 USD
+2.89 (+1.94%)
At close:
152.07 USD
0 (0%)
After Hours:

This BLTE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. BLTE Profitability Analysis

1.1 Basic Checks

  • In the past year BLTE has reported negative net income.
  • In the past 5 years BLTE always reported negative net income.
  • In the past 5 years BLTE always reported negative operating cash flow.
BLTE Yearly Net Income VS EBIT VS OCF VS FCFBLTE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

  • BLTE's Return On Assets of -32.42% is in line compared to the rest of the industry. BLTE outperforms 48.19% of its industry peers.
  • BLTE has a better Return On Equity (-33.75%) than 61.14% of its industry peers.
Industry RankSector Rank
ROA -32.42%
ROE -33.75%
ROIC N/A
ROA(3y)-28.59%
ROA(5y)-32.16%
ROE(3y)-30.08%
ROE(5y)-34.27%
ROIC(3y)N/A
ROIC(5y)N/A
BLTE Yearly ROA, ROE, ROICBLTE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -10 -20 -30 -40 -50

1.3 Margins

  • BLTE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BLTE Yearly Profit, Operating, Gross MarginsBLTE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. BLTE Health Analysis

2.1 Basic Checks

  • There is no outstanding debt for BLTE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BLTE Yearly Shares OutstandingBLTE Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M
BLTE Yearly Total Debt VS Total AssetsBLTE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • There is no outstanding debt for BLTE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACCN/A
BLTE Yearly LT Debt VS Equity VS FCFBLTE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

  • BLTE has a Current Ratio of 24.31. This indicates that BLTE is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of BLTE (24.31) is better than 93.78% of its industry peers.
  • BLTE has a Quick Ratio of 24.31. This indicates that BLTE is financially healthy and has no problem in meeting its short term obligations.
  • BLTE has a Quick ratio of 24.31. This is amongst the best in the industry. BLTE outperforms 93.78% of its industry peers.
Industry RankSector Rank
Current Ratio 24.31
Quick Ratio 24.31
BLTE Yearly Current Assets VS Current LiabilitesBLTE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 50M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. BLTE Growth Analysis

3.1 Past

  • BLTE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -94.92%.
EPS 1Y (TTM)-94.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-118.75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 65.39% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y45.26%
EPS Next 2Y7.48%
EPS Next 3Y55.87%
EPS Next 5Y65.39%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BLTE Yearly Revenue VS EstimatesBLTE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B
BLTE Yearly EPS VS EstimatesBLTE Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 10 20 30 40

More info and screens

Find the best growth stocksShow best growing peers

1

4. BLTE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BLTE. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BLTE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BLTE Price Earnings VS Forward Price EarningsBLTE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BLTE Per share dataBLTE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as BLTE's earnings are expected to grow with 55.87% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.48%
EPS Next 3Y55.87%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BLTE Dividend Analysis

5.1 Amount

  • BLTE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BLTE Fundamentals: All Metrics, Ratios and Statistics

BELITE BIO INC - ADR

NASDAQ:BLTE (3/27/2026, 8:02:48 PM)

After market: 152.07 0 (0%)

152.07

+2.89 (+1.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-02
Earnings (Next)05-11
Inst Owners18.61%
Inst Owner Change263.54%
Ins Owners1.21%
Ins Owner Change0%
Market Cap5.70B
Revenue(TTM)N/A
Net Income(TTM)-49.28M
Analysts84.29
Price Target215.73 (41.86%)
Short Float %4.05%
Short Ratio3.7
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-24.07%
Min EPS beat(2)-30.72%
Max EPS beat(2)-17.41%
EPS beat(4)0
Avg EPS beat(4)-17.04%
Min EPS beat(4)-30.72%
Max EPS beat(4)-1.93%
EPS beat(8)3
Avg EPS beat(8)-7.33%
EPS beat(12)4
Avg EPS beat(12)-15.81%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)11.24%
PT rev (3m)14.74%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.72%
EPS NY rev (1m)-0.75%
EPS NY rev (3m)-1.33%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 39.16
P/tB 39.16
EV/EBITDA N/A
EPS(TTM)-2.3
EYN/A
EPS(NY)-1.26
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS3.88
TBVpS3.88
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -32.42%
ROE -33.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-28.59%
ROA(5y)-32.16%
ROE(3y)-30.08%
ROE(5y)-34.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 24.31
Quick Ratio 24.31
Altman-Z N/A
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)261.74%
Cap/Depr(5y)203.71%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-94.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-118.75%
EPS Next Y45.26%
EPS Next 2Y7.48%
EPS Next 3Y55.87%
EPS Next 5Y65.39%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-53.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year38.62%
EBIT Next 3Y93.09%
EBIT Next 5Y91.2%
FCF growth 1Y1.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.02%
OCF growth 3YN/A
OCF growth 5YN/A

BELITE BIO INC - ADR / BLTE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of BELITE BIO INC - ADR (BLTE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to BLTE.


What is the valuation status for BLTE stock?

ChartMill assigns a valuation rating of 1 / 10 to BELITE BIO INC - ADR (BLTE). This can be considered as Overvalued.


How profitable is BELITE BIO INC - ADR (BLTE) stock?

BELITE BIO INC - ADR (BLTE) has a profitability rating of 1 / 10.


What is the earnings growth outlook for BELITE BIO INC - ADR?

The Earnings per Share (EPS) of BELITE BIO INC - ADR (BLTE) is expected to grow by 45.26% in the next year.